Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Hypertensive Disorders of Pregnancy
Author(s): Ariana Traub , Apoorva Sharma , Maria Carolina Gongora Added: 1 year ago

Prevention & Chronic Conditions
AHA 25: Pregnancy and CKM Health: Essential Knowledge for Cardiologists
Author(s): Emily Lau Added: 2 months ago
AHA Scientific Sessions 2025 - Dr Emily Lau (Brigham and Women's Hospital, US) joins us to discuss what cardiologists need to know about the intersection of pregnancy and cardiovascular-kidney-metabolic health, from pre-conception counseling through long-term postpartum care.Interview Questions:Why is it important for cardiologists to understand the relationship between pregnancy and… View more

Cardiovascular Renal Metabolic

CV Disease in Special Populations
AHA 25: HFpEF as an Adipose Tissue Disorder
Author(s): Milton Packer Added: 2 months ago
AHA Scientific Sessions 2025 - Dr Milton Packer (Baylor University Medical Center, US) joins us to discuss his novel unifying hypothesis that heart failure with preserved ejection fraction arises primarily from visceral adipose tissue dysfunction and altered adipokine signaling, rather than as a heterogeneous disorder driven by multiple comorbidities.Interview Questions:Can you explain the core… View more

Cardiovascular Renal Metabolic

Heart Failure
ESC 25 Guidelines Discussion: Management of Cardiovascular Disease and Pregnancy
Author(s): Harriette Van Spall , Julie De Backer Added: 4 months ago
ESC Congress 2025 - Late-breaker host Dr Harriette Van Spall (McMaster University, CA) joins Prof Julie De Backer (University Hospital Ghent, BE) to discuss the newly released 2025 ESC Guidelines for the Management of Cardiovascular Disease in Pregnancy. Together, they highlight key updates, critical advances in maternal cardiovascular care, and evidence-based recommendations tailored for this… View more

CV Disease in Special Populations

Guidelines & Statements
New ESC Guidelines for the Management of Hypertension
Author(s): Rhian Touyz Added: 1 year ago
ESC Congress 2024 — Dr Rhian Touyz (McGill University Health Center, CA) joins us to discuss key highlights from the ESC 2024 guidelines for the management of elevated blood pressure and hypertension.The new guidelines introduce a new systolic blood pressure treatment target range of 120-129 mmHg, placing emphasis on an intensive target treatment as the first step in patient management - only… View more

Prevention & Chronic Conditions
AHA 23 Late-Breaker Discussion: Hypertension Treatment in Nigeria Program
Author(s): Harriette Van Spall , Dike Bevis Ojji Added: 2 years ago
AHA 2023 — Investigator Dr Dike Bevis Ojji (University of Abuja, NG) talks with Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) about the Hypertension Treatment in Nigeria Program (NCT04158154).The aim of this study (Washington University School of Medicine) and employing an interrupted time series design, is to assess the implementation and evaluation of a culturally- and… View more

Prevention & Chronic Conditions
Ian Wilkinson
Job title: President of the British and Irish Hypertension Society and Professor of Therapeutics
Prof Ian Wilkinson is President of the British and Irish Hypertension Society and leads the Division of Experimental Medicine and Immunotherapeutics at the University of Cambridge. He has over 25 years of research experience in hypertension, leading national trials including AIMHY Trial and POPPY Study. He directs the Cambridge Clinical Trials Unit and provides specialist hypertension services,… View more
Research Area(s) / Expertise: Job title: T32 Postdoctoral Researcher, Clinical Instructor of Medicine, Division of Cardiology
Agnes Koczo is a post-doctoral researcher and cardiologist at the University of Pittsburgh Medical Center. She completed both her residency and fellowship training with chief designation at the University of Pittsburgh and with special focus on women's health. Her fellowship and post-doctoral research focuses on a number of cardiovascular conditions that exclusively or disproportionately impact… View more
ESC 25: The KARDIA-3 Study
Author(s): Neha Pagidipati Added: 4 months ago
ESC Congress 2025 - KARDIA 3 finds that a single dose of zilebesiran 300mg reduced office systolic blood pressure at month three compared to placebo, informing the dose, design and patient population for the upcoming zilebesiran phase III Cardiovascular outcomes trial.Dr Neha Pagidipati (Duke University Medical Center, US) joins us to discuss findings from the KARDIA-3 trial, evaluating… View more

Prevention & Chronic Conditions
ACC 25 Late-Breaking Discussion: The ADVANCE-HTN Trial
Author(s): Harriette Van Spall , Luke Laffin Added: 9 months ago
ACC 25 - ADVANCE-HTN shows lorundrostat, an aldosterone synthase inhibitor, effectively lowered 24-hour blood pressure in patients with uncontrolled and true resistant hypertension.Late-breaker discussion host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Luke Laffin (Cleveland Clinic, Cleveland, OH, US) to discuss the key findings from the ADVANCE-HTN trial… View more

Prevention & Chronic Conditions